China-based Luye Pharma Group (HKG: 2186) announced that its subsidiary Shandong BoAn Biotechnology Co., Ltd’s in-house developed CD25 monoclonal antibody (mAb) BA1106 has received clinical trial approval from the National Medical Products Administration (NMPA). This makes BA1106 the first CD25-targeted drug to enter clinical trials in China for the treatment of solid tumors.
Mechanism of Action
CD25, also known as interleukin-2 receptor alpha subunit (IL-2Rα), is highly expressed in regulatory T cells (Treg cells). Treg cells play an inhibitory role in various immune cells and are a key factor in the poor prognosis of most solid tumors. Eliminating Treg cells in the tumor microenvironment has become a key strategy for anti-tumor immunotherapy. BA1106, developed using BoAn’s fully human antibody transgenic mice and phage display technology platform, reduces Treg cells in the tumor microenvironment and increases the proportion of effector T cells through antibody-dependent cell-mediated cytotoxicity (ADCC) effects.
Preclinical Study Results
Preclinical studies have shown that BA1106 produces therapeutic effects in both early and advanced tumor models and demonstrates synergy when combined with an anti-PD-1 antibody. Importantly, BA1106 does not block the IL-2 signaling pathway and has a moderate and specific killing effect on Treg cells. These findings have been published in Scientific Reports.-Fineline Info & Tech
